309 related articles for article (PubMed ID: 28238096)
1. Clinical impact of galectin-3 in newly diagnosed t (15;17)(q22;q21)/PML-RARa acute promyelocytic leukemia treated with all-trans retinoic acid and arsenic trioxide-based regimens.
Gao N; Wang XX; Sun JR; Yu WZ; Li XZ
Ann Hematol; 2017 May; 96(5):711-718. PubMed ID: 28238096
[TBL] [Abstract][Full Text] [Related]
2. Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy.
Lou Y; Suo S; Tong H; Ye X; Wang Y; Chen Z; Qian W; Meng H; Mai W; Huang J; Tong Y; Jin J
Leuk Res; 2013 Nov; 37(11):1451-6. PubMed ID: 23958062
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.
Testa U; Lo-Coco F
Ann Hematol; 2016 Apr; 95(5):673-80. PubMed ID: 26920716
[TBL] [Abstract][Full Text] [Related]
4. Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide.
Shepshelovich D; Oniashvili N; Parnes D; Klein A; Muchtar E; Yeshaya J; Aviram A; Rabizadeh E; Raanani P
Cancer Genet; 2015 Nov; 208(11):575-9. PubMed ID: 26471811
[TBL] [Abstract][Full Text] [Related]
5. Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients.
Lou Y; Ma Y; Sun J; Ye X; Pan H; Wang Y; Qian W; Meng H; Mai W; He J; Tong H; Jin J
Ann Hematol; 2015 Nov; 94(11):1829-37. PubMed ID: 26294332
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy.
Lou Y; Ma Y; Suo S; Ni W; Wang Y; Pan H; Tong H; Qian W; Meng H; Mai W; Huang J; Yu W; Wei J; Mao L; Jin J
Leuk Res; 2015 Sep; 39(9):938-44. PubMed ID: 26183877
[TBL] [Abstract][Full Text] [Related]
8. Acute promyelocytic leukemia with cryptic t(15;17) on isochromosome 17: a case report and review of literature.
Tang Y; Wang Y; Hu L; Meng F; Xu D; Wan K; Huang L; Li C; Zhou J
Int J Clin Exp Pathol; 2015; 8(11):15294-300. PubMed ID: 26823883
[TBL] [Abstract][Full Text] [Related]
9. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.
Grimwade D; Jovanovic JV; Hills RK; Nugent EA; Patel Y; Flora R; Diverio D; Jones K; Aslett H; Batson E; Rennie K; Angell R; Clark RE; Solomon E; Lo-Coco F; Wheatley K; Burnett AK
J Clin Oncol; 2009 Aug; 27(22):3650-8. PubMed ID: 19506161
[TBL] [Abstract][Full Text] [Related]
10. PHA-Induced Peripheral Blood Cytogenetics and Molecular Analysis: a Valid Diagnostic and Follow-up Modality for Acute Promyelocytic Leukemia Patients Treated with ATRA and/or Arsenic Tri-oxide.
Baba SM; Azad NA; Shah ZA; Afroze D; Pandith AA; Jan A; Aziz SA; Dar FA
Asian Pac J Cancer Prev; 2016; 17(4):1999-2006. PubMed ID: 27221887
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734
[TBL] [Abstract][Full Text] [Related]
12. ider(17)(q10)t(15;17) associated with relapse and poor prognosis in a pediatric patient with acute promyelocytic leukemia.
Kim MJ; Yoon HS; Cho SY; Lee HJ; Suh JT; Lee J; Yoon HJ; Lee WI; Park TS
Cancer Genet Cytogenet; 2010 Sep; 201(2):116-21. PubMed ID: 20682396
[TBL] [Abstract][Full Text] [Related]
13. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.
Lucena-Araujo AR; Kim HT; Jacomo RH; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Chauffaille Mde L; Chiattone CS; Lima AS; Ruiz-Argüelles G; Undurraga MS; Martinez L; Kwaan HC; Gallagher R; Niemeyer CM; Schrier SL; Tallman MS; Grimwade D; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Sanz MA; Rego EM
Ann Hematol; 2014 Dec; 93(12):2001-10. PubMed ID: 24981688
[TBL] [Abstract][Full Text] [Related]
14. Expression of PML-RARα is up-regulated during ATRA and arsenics combined induction without influence on long-term prognosis of acute promyelocytic leukemia.
Zhu HH; Qin YZ; Lai YY; Shi HX; Liu YR; Jiang B; Huang XJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):872-8. PubMed ID: 23998577
[TBL] [Abstract][Full Text] [Related]
15. Recurrent extramedullary relapse of acute promyelocytic leukemia after allogeneic stem cell transplantation: successful treatment by arsenic trioxide in combination with local radiotherapy.
Kai T; Kimura H; Shiga Y; Ogawa K; Sato H; Maruyama Y
Int J Hematol; 2006 May; 83(4):337-40. PubMed ID: 16757435
[TBL] [Abstract][Full Text] [Related]
16. Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution.
Hu J; Shen ZX; Sun GL; Chen SJ; Wang ZY; Chen Z
Int J Hematol; 1999 Dec; 70(4):248-60. PubMed ID: 10643151
[TBL] [Abstract][Full Text] [Related]
17. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.
Sanford D; Lo-Coco F; Sanz MA; Di Bona E; Coutre S; Altman JK; Wetzler M; Allen SL; Ravandi F; Kantarjian H; Cortes JE
Br J Haematol; 2015 Nov; 171(4):471-7. PubMed ID: 26205361
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.
Adès L; Thomas X; Bresler AG; Raffoux E; Spertini O; Vey N; Marchand T; Récher C; Pigneux A; Girault S; Deconinck E; Gardin C; Tournilhac O; Lambert JF; Chevallier P; de Botton S; Lejeune J; Dombret H; Chevret S; Fenaux P
Haematologica; 2018 Dec; 103(12):2033-2039. PubMed ID: 30026341
[TBL] [Abstract][Full Text] [Related]
19. Acute promyelocytic leukemia relapsing as secondary acute myelogenous leukemia with translocation t(3;21)(q26;q22) and RUNX1-MDS1-EVI1 fusion transcript.
Park TS; Choi JR; Yoon SH; Song J; Kim J; Kim SJ; Kwon O; Min YH
Cancer Genet Cytogenet; 2008 Dec; 187(2):61-73. PubMed ID: 19027486
[TBL] [Abstract][Full Text] [Related]
20. Advances in therapies for acute promyelocytic leukemia.
Kamimura T; Miyamoto T; Harada M; Akashi K
Cancer Sci; 2011 Nov; 102(11):1929-37. PubMed ID: 21790894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]